Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon? (Q34124133)

31 July 2017

1 reference

title

Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon? (English)

1 reference

31 July 2017

A T Davis

1

1 reference

31 July 2017

publication date

1 October 2000

1 reference

31 July 2017

published in

Seminars in Hematology

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

4 Suppl 7

1 reference

31 July 2017

page(s)

34-42

1 reference

Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies, II.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

The TRAIL to selective tumor death

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Transplantation of anergic histoincompatible bone marrow allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Designing and optimizing library selection strategies for generating high-affinity antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1)

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990058-1

7 January 2021

10.1016/S0037-1963(00)90058-1

Identifiers

DOI

1 reference

31 July 2017

1 reference